niacinamide and Acute Myelogenous Leukemia studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

Excerpt	Relevance	Reference
"Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12."	9.15	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)
"Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein."	6.73	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. ( Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W, 2008)
"The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al."	5.38	Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012)
"Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12."	5.15	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)
" In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation."	5.15	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011)
"A 10-year-old boy with FLT3-ITD-positive acute myelogenous leukemia who developed PRES during sorafenib treatment has been presented here."	3.83	Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia. ( Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S, 2016)
"To evaluate the clinical activity of sequential therapy with sorafenib and sunitinib in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myelogenous leukemia (AML) and monitor the emergence of secondary FLT3 tyrosine kinase domain (TKD) mutations during treatment."	3.79	Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. ( Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI, 2013)
"We compared the antitumor activities of the multitargeted tyrosine kinase inhibitors imatinib, sorafenib, and sunitinib to determine which inhibitor is best suited to be used for the treatment of acute myelogenous leukemia (AML)."	3.74	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. ( Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A, 2008)
"Patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations (FLT3-ITD+) who relapse after allogeneic transplantation (allo-SCT) have a very dismal prognosis with the currently available treatment options."	2.84	Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. ( Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017)
"Sorafenib was initiated between days 45 and 120 after HSCT and continued for 12 28-day cycles."	2.79	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. ( Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S, 2014)
"Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response."	2.78	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. ( Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA, 2013)
"The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy."	2.78	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. ( Aulitzky, W; Berdel, WE; Blau, I; Brandts, C; Brunnberg, U; Duyster, J; Ehninger, G; Fischer, T; Giagounidis, A; Heinecke, A; Krämer, A; Kreuzer, KA; Krug, U; Kunzmann, V; Müller-Tidow, C; Neubauer, A; Noppeney, R; Ottmann, O; Reichle, A; Sauerland, MC; Schaich, M; Serve, H; Steffen, B; Stuhlmann, R; Thiede, C; Wagner, R; Wandt, H, 2013)
"Sorafenib is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)."	2.78	A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. ( Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W, 2013)
"The sorafenib response was lost in most patients after 72 (range 54-287) days but the FLT3 and downstream effectors remained suppressed."	2.77	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. ( Cheung, AM; Choi, WW; Chow, HC; Eaves, C; Fung, TK; Han, HH; Ho, C; Kwong, YL; Leung, AY; Lok, S; Ma, AC; Man, CH, 2012)
"Our data demonstrate that acute myeloid leukemia cells show a variable but overall good susceptibility to the innovative therapeutic combination of sorafenib+nutlin-3, which differentially involves the pro-apoptotic Bcl-2 family members Bax and Bak in p53(wild-type) and p53(deleted) cells."	2.77	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. ( Celeghini, C; di Iasio, MG; Lanza, F; Melloni, E; Ongari, M; Secchiero, P; Tiribelli, M; Voltan, R; Zauli, G, 2012)
"Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein."	2.73	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. ( Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W, 2008)
"We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al."	2.72	Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. ( Chow, S; Hedley, D; Tong, FK, 2006)
"Although both reached severe aplasia of the bone marrow without blastic infiltration, death occurred with neutropenic sepsis."	2.52	Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. ( Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D, 2015)
"Sorafenib is used for the treatment of acute myeloid leukemia patients carrying internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) mutation."	2.52	A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. ( Mihaila, RG, 2015)
"Survival of patients with acute myelogenous leukemia (AML), particularly in younger patients, has improved in recent years due to improved understanding of disease biology, post remission therapies and supportive care."	2.50	Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. ( Hu, B; Mohty, M; Savani, BN; Vikas, P, 2014)
"Treatment of acute myeloid leukemia remains a therapeutic challenge."	2.49	Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. ( Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D, 2013)
"The treatment of acute myeloid leukemia has not changed significantly over the last 40 years."	2.48	Molecular targeted therapy in acute myeloid leukemia. ( Cortes, J; Daver, N, 2012)
" In this article, we describe the application of flow cytometry to the pharmacodynamic monitoring of molecular-targeted agents in leukemia patients."	2.44	Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. ( Chow, S; Goolsby, C; Hedley, DW; Shankey, TV, 2008)
"5) after allogeneic HSCT with a median daily dosage of 400 mg (range: 200-800) orally, and lasted a median of 11."	1.72	Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. ( Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F, 2022)
"Sorafenib dosing was individualized, starting at 200 mg twice a day (BID), and titrated based on tolerability or toxicities until a tolerable dose was identified."	1.56	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. ( Baer, MR; Dezern, A; Duong, VH; Emadi, A; Gocke, C; Gojo, I; Greer, J; Jones, RJ; Karp, J; Levis, M; Pratz, KW; Rosner, G; Rudek, MA; Smith, BD; Wright, JJ; Zahurak, M, 2020)
"We studied three FLT3 ITD acute myeloid leukemia (AML) patients who relapsed after allogeneic haematopoietic stem cell transplantation (alloHSCT) and received multikinase inhibitor (MKI) sorafenib as part of salvage therapy."	1.48	The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. ( Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A, 2018)
"To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT)."	1.48	[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation]. ( Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X, 2018)
"Sorafenib treatment after HSCT appears to be feasible and highly effective with dose individualization according to patient tolerability."	1.46	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. ( Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A, 2017)
"Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT."	1.46	Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. ( Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E, 2017)
"Sorafenib is a promising agent for treating pediatric refractory acute myeloid leukemia (AML) exhibiting FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD); however, its optimal use needs to be established."	1.46	Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports. ( Hosoi, H; Imamura, T; Ishida, H; Kanayama, T; Kawashima-Goto, S; Miyachi, M; Nakatani, T; Osone, S; Sugimoto, A; Takai, A; Tamura, S; Tsuma, Y, 2017)
"To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML)."	1.43	[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. ( DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016)
"Sorafenib was associated with improved 2-year PFS (82% vs."	1.43	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. ( Alyea, EP; Antin, JH; Ballen, KK; Brunner, AM; Chen, YB; Collier, K; Connolly, C; Cutler, CS; Deangelo, DJ; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Koreth, J; Li, S; McAfee, SL; Nikiforow, S; Soiffer, RJ; Spitzer, TR; Stone, RM; Wadleigh, M, 2016)
"Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission, and sorafenib monotherapy as mauntenance treatment after complete remission (CR)."	1.43	[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation]. ( Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y, 2016)
"FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid leukemia (AML) portends a poor prognosis, and ineffective targeting of the leukemic stem cell (LSC) population remains one of several obstacles in treating this disease."	1.43	All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. ( Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D, 2016)
" In 5 patients with pronounced toxicity, we switched to an alternating dosing schedule with 1 month on/1 month off sorafenib."	1.42	Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. ( Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A, 2015)
"Sorafenib was initiated at a median of 100 days post HSCT."	1.42	Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. ( Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A, 2015)
"Sorafenib is a tyrosine kinase inhibitor active against RAF, VEGF, and FLT3-ITD."	1.42	Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. ( Antar, A; Bazarbachi, A; Kharfan-Dabaja, MA; Mahfouz, R, 2015)
"FLT3(ITD) subtype acute myeloid leukemia (AML) has a poor prognosis with currently available therapies."	1.40	FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. ( D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y, 2014)
"Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation."	1.39	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. ( Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X, 2013)
"The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al."	1.38	Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012)
"Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML)."	1.38	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. ( Berdel, WE; Brandts, C; Ehninger, G; Haibach, M; Hentrich, M; Junghanß, C; Krämer, A; Kramer, M; Krause, SW; Müller-Tidow, C; Pflüger, KH; Ritter, B; Röllig, C; Schleyer, E; Serve, H; Shaid, S, 2012)
"We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute myeloid leukemia patients with relapsed patients."	1.37	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. ( Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X, 2011)
"Sorafenib in combination with cytarabine resulted in strong anti-AML activity in vitro and in vivo."	1.37	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. ( Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S, 2011)
"Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT)."	1.37	Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. ( Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M, 2011)
"Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway."	1.37	Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. ( Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F, 2011)
"We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen."	1.36	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. ( Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010)
" Exposure of cells to noninducing concentrations of these compounds caused a leftward shift in the dose-response curve for RA; maturation was observed at 10(-11) M RA in the presence of either 2 mM NAm or 0."	1.27	Maturation of human promyelocytic leukemia cells induced by nicotinamide: evidence of a regulatory role for ADP-ribosylation of chromosomal proteins. ( Davies, PJ; Johnson, GS; Lucas, DL; Tanuma, S; Wright, DG, 1984)

Research

Studies (137)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (2.92)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (8.03)	29.6817
2010's	116 (84.67)	24.3611
2020's	6 (4.38)	2.80

Authors	Studies
Aydin, S	1
Passera, R	1
Scaldaferri, M	1
Dellacasa, CM	1
Poggiu, M	1
Cattel, F	1
Zallio, F	1
Brunello, L	1
Giaccone, L	1
Dogliotti, I	1
Busca, A	1
Ai, H	3
Mi, RH	1
Chen, L	1
Ji, X	1
Yin, QS	1
Wei, XD	1
Song, YP	2
Pratz, KW	6
Rudek, MA	4
Smith, BD	5
Karp, J	1
Gojo, I	1
Dezern, A	1
Jones, RJ	3
Greer, J	1
Gocke, C	1
Baer, MR	1
Duong, VH	1
Rosner, G	1
Zahurak, M	1
Wright, JJ	3
Emadi, A	2
Levis, M	10
Jones, CL	1
Stevens, BM	1
Pollyea, DA	1
Culp-Hill, R	1
Reisz, JA	1
Nemkov, T	1
Gehrke, S	1
Gamboni, F	1
Krug, A	1
Winters, A	1
Pei, S	1
Gustafson, A	1
Ye, H	1
Inguva, A	1
Amaya, M	1
Minhajuddin, M	1
Abbott, D	1
Becker, MW	1
DeGregori, J	1
Smith, CA	1
D'Alessandro, A	1
Jordan, CT	2
Zhang, TY	1
Majeti, R	1
Damnernsawad, A	1
Bottomly, D	1
Kurtz, SE	1
Eide, CA	1
McWeeney, SK	1
Tyner, JW	1
Nechiporuk, T	1
Battipaglia, G	1
Ruggeri, A	1
Massoud, R	1
El Cheikh, J	1
Jestin, M	1
Antar, A	2
Ahmed, SO	1
Rasheed, W	1
Shaheen, M	1
Belhocine, R	1
Brissot, E	1
Dulery, R	1
Eder, S	1
Giannotti, F	1
Isnard, F	1
Lapusan, S	1
Rubio, MT	1
Vekhoff, A	1
Aljurf, M	1
Legrand, O	1
Mohty, M	2
Bazarbachi, A	2
Roolf, C	1
Dybowski, N	1
Sekora, A	1
Mueller, S	1
Knuebel, G	1
Tebbe, A	1
Murua Escobar, H	1
Godl, K	1
Junghanss, C	1
Schaab, C	1
Bruner, JK	2
Ma, HS	2
Li, L	4
Qin, ACR	1
Levis, MJ	2
Pratilas, CA	1
Small, D	5
Metzelder, SK	5
Schroeder, T	4
Lübbert, M	2
Ditschkowski, M	1
Götze, K	2
Scholl, S	4
Meyer, RG	2
Dreger, P	2
Basara, N	2
Fey, MF	1
Salih, HR	2
Finck, A	2
Pabst, T	1
Giagounidis, A	4
Kobbe, G	4
Wollmer, E	2
Finke, J	1
Neubauer, A	7
Burchert, A	6
Lange, A	1
Jaskula, E	1
Lange, J	1
Dworacki, G	1
Nowak, D	1
Simiczyjew, A	1
Mordak-Domagala, M	1
Sedzimirska, M	1
Xuan, L	2
Fan, ZP	1
Zhang, Y	5
Xu, N	2
Ye, JY	1
Zhou, X	1
Wang, ZX	1
Sun, J	4
Liu, QF	1
Huang, F	2
Smith, CC	1
Lasater, EA	1
Zhu, X	2
Lin, KC	1
Stewart, WK	1
Damon, LE	1
Salerno, S	1
Shah, NP	1
Ravandi, F	11
Alattar, ML	1
Grunwald, MR	1
Rajkhowa, T	3
Richie, MA	1
Pierce, S	3
Daver, N	4
Garcia-Manero, G	5
Faderl, S	5
Nazha, A	1
Konopleva, M	12
Borthakur, G	8
Burger, J	1
Kadia, T	1
Dellasala, S	1
Andreeff, M	13
Cortes, J	8
Kantarjian, H	8
Chandran, P	1
Gupta, N	1
Retnakumari, AP	1
Malarvizhi, GL	1
Keechilat, P	1
Nair, S	1
Koyakutty, M	1
Wolleschak, D	1
Schalk, E	1
Krogel, C	1
Schnoeder, TM	1
Luehr, H	1
Jentsch-Ullrich, K	1
Fischer, T	2
Heidel, FH	2
Serve, H	3
Krug, U	3
Wagner, R	1
Sauerland, MC	1
Heinecke, A	1
Brunnberg, U	1
Schaich, M	2
Ottmann, O	1
Duyster, J	2
Wandt, H	1
Reichle, A	2
Aulitzky, W	2
Noppeney, R	2
Blau, I	1
Kunzmann, V	2
Stuhlmann, R	2
Krämer, A	3
Kreuzer, KA	1
Brandts, C	2
Steffen, B	1
Thiede, C	2
Müller-Tidow, C	3
Ehninger, G	4
Berdel, WE	3
Baker, SD	6
Zimmerman, EI	2
Wang, YD	1
Orwick, S	4
Zatechka, DS	1
Buaboonnam, J	2
Neale, GA	1
Olsen, SR	1
Enemark, EJ	1
Shurtleff, S	1
Rubnitz, JE	3
Mullighan, CG	1
Inaba, H	5
Jiang, ZH	1
Feng, FE	1
Lin, XQ	1
Lu, J	1
Johnston, DL	1
Nagarajan, R	1
Caparas, M	1
Schulte, F	1
Cullen, P	1
Aplenc, R	1
Sung, L	1
Turner, DC	1
Hu, S	3
Roberts, MS	1
Janke, LJ	1
Ramachandran, A	2
Stewart, CF	1
Fontanelli, G	1
Rocco, M	1
Caracciolo, F	1
Benedetti, E	1
Buda, G	1
Orciuolo, E	1
Carulli, G	1
Galimberti, S	1
Azzarà, A	1
Petrini, M	1
Hu, B	1
Vikas, P	1
Savani, BN	1
Arana Yi, C	1
Cortes, JE	6
Jabbour, E	1
O'Brien, S	2
Estrov, Z	4
Thomas, D	3
Brandt, M	3
Pratz, K	2
Luthra, R	4
Keegan, K	1
Li, C	1
Li, Z	1
Ma, J	2
Ragains, M	1
Coberly, S	1
Hollenback, D	1
Eksterowicz, J	1
Liang, L	1
Weidner, M	2
Huard, J	2
Wang, X	2
Alba, G	1
Orf, J	1
Lo, MC	1
Zhao, S	1
Ngo, R	1
Chen, A	1
Liu, L	1
Carlson, T	1
Quéva, C	1
McGee, LR	1
Medina, J	1
Kamb, A	1
Wickramasinghe, D	1
Dai, K	1
Man, CH	4
Lam, SS	2
Sun, MK	1
Chow, HC	3
Gill, H	3
Kwong, YL	4
Leung, AY	4
Zhang, W	5
Gao, C	1
Chen, Y	1
Jacamo, RO	1
Guenounou, S	1
Delabesse, E	1
Récher, C	1
Alvarado, Y	1
Kantarjian, HM	3
Pemmaraju, N	1
Sammons, SL	1
Karp, JE	2
Liegel, J	1
Courville, E	1
Sachs, Z	1
Ustun, C	1
Fathi, AT	3
Lin, WM	1
Durazzo, T	1
Piris, A	1
Sadrzadeh, H	1
Bernardo, L	1
Borger, DR	1
McAfee, SL	2
Kroshinsky, D	1
Chen, YB	3
Cummins, KD	1
Jane, SM	1
Ninkovic, S	1
Nikovic, S	1
Bazargan, A	1
Filshie, R	1
Sutrave, G	1
Hertzberg, M	1
Scott, A	1
Lane, S	1
Yannakou, CK	1
Ritchie, D	1
D'Rozario, J	1
Black, J	1
Bavishi, K	1
Wei, A	2
Song, G	1
Valdez, BC	1
Li, Y	1
Liu, Y	2
Champlin, RE	2
Andersson, BS	1
Li, S	2
Lane, AA	1
Connolly, C	2
Del Rio, C	1
Valles, B	1
Curtis, M	1
Ballen, K	1
Cutler, C	1
Dey, BR	2
El-Jawahri, A	2
Ho, VT	2
Joyce, A	1
McAfee, S	1
Rudek, M	1
Verselis, S	1
Antin, JH	2
Spitzer, TR	2
Soiffer, R	1
Hsu, CP	1
Lu, JF	1
Kuchimanchi, M	1
Sun, YN	1
Xu, G	1
Xu, Y	1
D'Argenio, DZ	1
Galanis, A	1
Kuo, YH	1
Bhatia, R	1
Bruedigam, C	1
Bagger, FO	1
Paine Kuhn, C	1
Guignes, S	1
Song, A	1
Austin, R	1
Vu, T	1
Lee, E	1
Riyat, S	1
Moore, AS	2
Lock, RB	2
Bullinger, L	1
Hill, GR	1
Armstrong, SA	1
Williams, DA	1
Lane, SW	1
Kharfan-Dabaja, MA	1
Mahfouz, R	1
Tarlock, K	1
Chang, B	1
Cooper, T	2
Gross, T	1
Gupta, S	1
Neudorf, S	1
Adlard, K	1
Ho, PA	1
McGoldrick, S	1
Watt, T	1
Templeman, T	1
Sisler, I	1
Garee, A	1
Thomson, B	1
Woolfrey, A	1
Estey, E	1
Meshinchi, S	1
Pollard, JA	1
Fouladi, F	1
Jehn, LB	1
Hub, F	1
Henkenius, K	1
Brendel, C	2
Stiewe, T	2
Ip, AH	1
Choi, WW	2
Liu, S	1
Wei, X	2
Yin, Q	2
Mi, R	2
Wang, P	2
Zhao, H	1
Han, L	1
Song, Y	1
Yılmaz Karapınar, D	1
Karadaş, N	1
Önder Siviş, Z	1
Balkan, C	1
Kavaklı, K	1
Aydınok, Y	1
Xu, H	1
Giri, S	1
Hamdeh, S	1
Bhatt, VR	1
Schwarz, JK	1
Michel, C	1
von Bonin, M	2
Rehberger, M	1
Hessmann, E	1
Inselmann, S	1
Solovey, M	1
Wang, Y	1
Sohlbach, K	1
Charles, J	1
Ten Haaf, A	1
Ellenrieder, V	1
Gattenlöhner, S	1
Bornhäuser, M	2
Lim, Y	1
Gondek, L	1
Wang, Q	1
Ma, H	2
Chang, E	1
Huso, DL	1
Foerster, S	1
Marchionni, L	1
McGovern, K	1
Watkins, DN	1
Peacock, CD	1
Merchant, AA	1
Matsui, W	1
Tschan-Plessl, A	1
Halter, JP	1
Heim, D	1
Medinger, M	1
Passweg, JR	1
Gerull, S	1
De Freitas, T	1
Marktel, S	1
Piemontese, S	1
Carrabba, MG	1
Tresoldi, C	1
Messina, C	1
Lupo Stanghellini, MT	1
Assanelli, A	1
Corti, C	1
Bernardi, M	1
Peccatori, J	1
Vago, L	1
Ciceri, F	1
Muppidi, MR	1
Portwood, S	1
Griffiths, EA	1
Thompson, JE	1
Ford, LA	1
Freyer, CW	1
Wetzler, M	1
Wang, ES	1
Badar, T	1
Nogueras-Gonzalez, GM	1
Garcia Manero, G	1
Kadia, TM	1
Wierda, WG	1
Patel, K	1
Oran, B	1
Champlin, R	1
Wang, R	1
Xia, L	1
Gabrilove, J	1
Waxman, S	1
Jing, Y	1
Dahl, NA	1
Michaels, ST	1
McMasters, RL	1
Chandra, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1 Open-label Study of KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia[NCT04914845]	Phase 1	40 participants (Anticipated)	Interventional	2021-08-27	Recruiting
Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227)[NCT01254890]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2011-01-31	Completed
Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation[NCT01398501]	Phase 1	22 participants (Actual)	Interventional	2011-08-31	Completed
Multicenter, Observational Trial to Determine the Response Rate of Sorafenib and Donor Lymphocyte Infusions (DLI) Versus Best Available Treatment (BAT) in FLT3-ITD-mutant AML Relapse After Allogeneic Hematopoietic Cell Transplantation[NCT02867891]		396 participants (Actual)	Observational	2001-03-31	Completed
A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age[NCT00893373]	Phase 2	276 participants (Actual)	Interventional	2009-03-31	Completed
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial[NCT05404516]	Phase 2	88 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia[NCT02474290]	Phase 2/Phase 3	202 participants (Actual)	Interventional	2015-06-20	Completed
Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646]	Phase 1	36 participants (Actual)	Interventional	2005-10-31	Completed
A Phase II Pilot Study of VELCADE in Patients With MDS[NCT00262873]	Phase 2	8 participants (Actual)	Interventional	2005-05-31	Completed
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015]	Early Phase 1	55 participants (Actual)	Interventional	2013-03-15	Completed
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114]	Phase 2	57 participants (Actual)	Interventional	2013-07-08	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

MTD is defined as highest dose level in which 6 patients treated with at most 1 experiencing a dose limiting toxicity (DLT) during 1st cycle. One cycle of therapy is 7 days of azacitidine (AZA) and 28 days of sorafenib. Starting dose of Sorafenib is 200 mg twice a day azacitidine (NCT01254890)
Timeframe: 28 day cycle

Phase II: Number of Participants With Response

Intervention	mg/twice daily (Number)
Azacitidine + Sorafenib	400

Response according to International Working Group response criteria for Acute myeloid leukemia (AML) (JCO 2003; 21: 4642-9): CR defined by presence of <5% blasts in the bone marrow (BM), with >1 X 10^9/L neutrophils and >100 x 10^9/L platelets in the peripheral blood (PB) with no detectable extramedullary disease. Participants who met the above criteria but had neutrophil or platelet counts less than the stated values were considered to have achieved CRi (CR with incomplete recovery of PB counts) or CR with incomplete platelet recovery (CRp) if CR but platelets < 100 x 10^9/L but ≥ 50 x 10^9/L and platelet transfusion independent. Partial response (PR) required all of the hematologic values for a CR but with a decrease of >/= 50% in the percentage of blasts to 5% to 25% in the BM aspirate. (NCT01254890)
Timeframe: 90 days

Number of Participants Who Experienced an Adverse Event

Average Number of Colony Forming Unit-granulocyte-macrophages in Bone Marrow

Intervention	participants (Number)
	Complete Response (CR)	Complete Remission Without Platelet Recovery (CRi)	Partial Response	Complete Response (CRp)	No Response
Azacitidine + Sorafenib	8	10	1	6	23

Intervention	participants (Number)
Bortezomib	6

Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14

Average Number of Erthroid Burst Forming Units in Bone Marrow

Intervention	number of colonies per 50000 cell plated (Mean)
	pre bortezomib	post bortezomib
Bortezomib	16.1	28.6

Average Number of Leukemia Forming Units in Bone Marrow

Intervention	number of colonies per 50000 cell plated (Mean)
	pre bortezomib	post bortezomib
Bortezomib	14.75	14.75

Average Percentage of Light Density Cells in Apoptosis

Intervention	number of colonies per 50000 cell plated (Mean)
	pre bortezomib	post bortezomib
Bortezomib	27.65	54.28

The CD34+ fraction of light density marrow obtained from patients at baseline and while receiving bortezomib were assessed through measurement of Annexin V (assay obtained form R&D Systems) and by flow cytometry analysis. (NCT00262873)
Timeframe: day 14

Interleukin 6 Levels in Serum

Intervention	percentage of apoptotic cells (Mean)
	pre bortezomib	post bortezomib
Bortezomib	6.68	11.37

"interleukin-6 levels were measured by enzyme-linked immunosorbant assay ELISA in serum from participants exposed to bortezomib.~Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial." (NCT00262873)
Timeframe: day 14

Vascular Endothelial Growth Factor (VEGF) Levels in Serum

Intervention	pg/ml (Mean)
	pre bortezomib	post bortezomib
Bortezomib	6.8	8.6

VEGF levels were measured by ELISA (R&DSystems) in serum from participants exposed to bortezomib. Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial. (NCT00262873)
Timeframe: day 14

Article	Year
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. Journal of hematology & oncology, 2013, Jun-11, Volume: 6 Topics: Aged; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-	2013
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert review of hematology, 2014, Volume: 7, Issue:2 Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell T	2014
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like	2014
[Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:3 Topics: Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib	2015
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3 Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols;	2015
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015, Volume: 159, Issue:4 Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage	2015
Potential role of sorafenib in the treatment of acute myeloid leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:12 Topics: Benzenesulfonates; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea	2008
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Current opinion in hematology, 2010, Volume: 17, Issue:2 Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Nia	2010
[Progression of sorafenib in the treatment of acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea	2011
Molecular targeted therapy in acute myeloid leukemia. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Human	2012
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia, 2012, Volume: 26, Issue:10 Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosi	2012
State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Current medicinal chemistry, 2012, Volume: 19, Issue:28 Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leuk	2012
FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1 Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans;	2007
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicologic pathology, 2008, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow C	2008
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicologic pathology, 2008, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow C	2008
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicologic pathology, 2008, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow C	2008
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicologic pathology, 2008, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow C	2008

Article	Year
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. International journal of hematology, 2022, Volume: 116, Issue:6 Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acut	2022
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022, 11-14, Volume: 43, Issue:11 Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans;	2022
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:2 Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acut	2020
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell stem cell, 2020, 11-05, Volume: 27, Issue:5 Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Ni	2020
Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML. Cell stem cell, 2020, 11-05, Volume: 27, Issue:5 Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Ni	2020
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia. Haematologica, 2022, 01-01, Volume: 107, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats;	2022
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer, 2017, Aug-01, Volume: 123, Issue:15 Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility	2017
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:7 Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; fms-Like Tyrosine Kinase 3; Gene Regulatory Net	2017
Midostaurin Gets FDA Nod for AML. Cancer discovery, 2017, Volume: 7, Issue:7 Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea	2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. Cancer research, 2017, 10-15, Volume: 77, Issue:20 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Prolifer	2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. European journal of cancer (Oxford, England : 1990), 2017, Volume: 86 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free	2017
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PloS one, 2018, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantat	2018
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation]. Zhonghua nei ke za zhi, 2018, May-01, Volume: 57, Issue:5 Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3;	2018
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood, 2013, Apr-18, Volume: 121, Issue:16 Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neo	2013
Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. Nanomedicine : nanotechnology, biology, and medicine, 2013, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Everolimus; Humans; Leukemia, Myeloi	2013
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20 Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neopl	2013
[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:8 Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinami	2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood, 2013, Nov-21, Volume: 122, Issue:22 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Ne	2013
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:1 Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine K	2014
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Molecular cancer therapeutics, 2014, Volume: 13, Issue:4 Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dos	2014
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood, 2014, Apr-17, Volume: 123, Issue:16 Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cation Transport Proteins; Cells, Cultured	2014
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-01, Volume: 20, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis;	2014
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. European journal of haematology, 2014, Volume: 93, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; fms-Like T	2014
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer, 2014, Jul-15, Volume: 120, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational An	2014
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. American journal of hematology, 2014, Volume: 89, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Tran	2014
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect. Haematologica, 2014, Volume: 99, Issue:11 Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoie	2014
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia,	2016
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood cancer journal, 2014, Aug-08, Volume: 4 Topics: Adolescent; Adult; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myel	2014
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides;	2014
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of pharmacokinetics and pharmacodynamics, 2014, Volume: 41, Issue:6 Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dis	2014
Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica, 2015, Volume: 100, Issue:3 Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Cl	2015
Pushing the limits: defeating leukemia stem cells by depleting telomerase. Cell stem cell, 2014, Dec-04, Volume: 15, Issue:6 Topics: Animals; Humans; Indoles; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Niacinamide; Telomerase;	2014
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell stem cell, 2014, Dec-04, Volume: 15, Issue:6 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Disease Models, Animal; Gene Expression	2014
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:5 Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; fms-Like Tyrosine Kinase 3; Gene Duplicatio	2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. Pediatric blood & cancer, 2015, Volume: 62, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease;	2015
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leukemia & lymphoma, 2015, Volume: 56, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signa	2015
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia. Haematologica, 2015, Volume: 100, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedu	2015
[CLAG regimen in combination with sorafenib in the treatment of refractory acute myeloid leukemia:a case report]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Niacinamide; Pheny	2015
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinas	2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia, 2015, Volume: 29, Issue:7 Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance,	2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Science translational medicine, 2015, Jun-10, Volume: 7, Issue:291 Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progres	2015
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Annals of hematology, 2015, Volume: 94, Issue:11 Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Tran	2015
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. European journal of haematology, 2016, Volume: 96, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit	2016
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15 Suppl Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Mye	2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms	2015
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Gene Expression Reg	2016
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation. Pediatric blood & cancer, 2016, Volume: 63, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome De	2016
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leukemia research, 2015, Volume: 39, Issue:12 Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosi	2015
Sorafenib and novel multikinase inhibitors in AML. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoa	2015
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Ne	2016
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML. Annals of hematology, 2016, Volume: 95, Issue:6 Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphoc	2016
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene, 2016, 09-29, Volume: 35, Issue:39 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Ne	2016
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]. Zhonghua nei ke za zhi, 2016, Apr-01, Volume: 55, Issue:4 Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem	2016
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem	2016
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood, 2016, 06-09, Volume: 127, Issue:23 Topics: Animals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine	2016
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer letters, 2016, 07-28, Volume: 377, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dos	2016
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Co	2016
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice. Haematologica, 2016, Volume: 101, Issue:8 Topics: Animals; Benzothiazoles; Drug Resistance; fms-Like Tyrosine Kinase 3; Gene Knock-In Techniques; Germ	2016
Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Survival	2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 2016, Jul-26, Volume: 7, Issue:30 Topics: Animals; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; fms-Like Tyrosine Kinase 3;	2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. British journal of haematology, 2016, Volume: 175, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; H	2016
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Zhonghua nei ke za zhi, 2016, Aug-01, Volume: 55, Issue:8 Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine K	2016
Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:4 Topics: Child; Child, Preschool; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoi	2017
Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia. Chinese medical journal, 2016, 10-20, Volume: 129, Issue:20 Topics: Adult; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide;	2016
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes. British journal of haematology, 2018, Volume: 180, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloi	2018
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene	2017
NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia. Oncotarget, 2016, Dec-27, Volume: 7, Issue:52 Topics: Animals; Cell Line, Tumor; Cytarabine; DNA (Cytosine-5-)-Methyltransferase 1; Humans; Leukemia, Myel	2016
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoiet	2017
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leukemia research, 2009, Volume: 33, Issue:2 Topics: Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenyl	2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, Oct-01, Volume: 114, Issue:14 Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Prolifer	2009
Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. American journal of hematology, 2009, Volume: 84, Issue:10 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloi	2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 2010, Feb-18, Volume: 115, Issue:7 Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line	2010
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount. Leukemia research, 2010, Volume: 34, Issue:10 Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 2010, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regul	2010
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leukemia research, 2010, Volume: 34, Issue:10 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host D	2010
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Annals of hematology, 2011, Volume: 90, Issue:4 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Fatal Outcome; fms-Like T	2011
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; DNA Mutational Ana	2010
Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anti-cancer drugs, 2011, Volume: 22, Issue:1 Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; DN	2011
Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Acta haematologica, 2010, Volume: 124, Issue:3 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Enzyme Activation; Female; fms-Like Tyrosine Kinase	2010
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leukemia research, 2011, Volume: 35, Issue:3 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase	2011
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia. Leukemia research, 2011, Volume: 35, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Blast Crisis; Bone Marrow Diseases; fms-Like Tyrosin	2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 2011, Mar-24, Volume: 117, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyr	2011
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia, 2011, Volume: 25, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clini	2011
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;	2011
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate	2011
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female;	2011
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. Bone marrow transplantation, 2012, Volume: 47, Issue:6 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Hematopoietic Stem Cell Transplantation; Humans; Le	2012
Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia. British journal of haematology, 2012, Volume: 157, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2012
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. Pediatric blood & cancer, 2012, Volume: 59, Issue:4 Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acut	2012
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Data Collection; Female; H	2012
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. British journal of haematology, 2012, Volume: 157, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leuk	2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia, 2012, Volume: 26, Issue:7 Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle	2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival;	2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, Volume: 26, Issue:11 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, Volume: 26, Issue:11 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, Volume: 26, Issue:11 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, Volume: 26, Issue:11 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia	2012
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. British journal of haematology, 2012, Volume: 158, Issue:4 Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kina	2012
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia. Leukemia & lymphoma, 2013, Volume: 54, Issue:4 Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea C	2013
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer letters, 2013, Feb-01, Volume: 329, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cellular Microenvironment; Coculture Te	2013
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3. Haematologica, 2012, Volume: 97, Issue:11 Topics: Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Ac	2012
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leukemia & lymphoma, 2013, Volume: 54, Issue:8 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, M	2013
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental hematology, 2007, Volume: 35, Issue:10 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screenin	2007
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia, 2008, Volume: 22, Issue:4 Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cell Line; Drug	2008
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular cancer therapeutics, 2008, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell	2008
Maturation of human promyelocytic leukemia cells induced by nicotinamide: evidence of a regulatory role for ADP-ribosylation of chromosomal proteins. Journal of cellular physiology, 1984, Volume: 121, Issue:2 Topics: Acyltransferases; Adenosine Diphosphate Ribose; Cell Division; Cell Line; Cell Nucleus; Humans; Kine	1984
N-methylnicotinamide as a possible prognostic indicator of recovery from leukaemia in patients treated with total-body irradiation and bone marrow transplants. Strahlentherapie, 1984, Volume: 160, Issue:4 Topics: Adult; Bone Marrow Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Pro	1984
Prevention of adriamycin-induced interphase death by 3-aminobenzamide and nicotinamide in a human promyelocytic leukemia cell line. Biochemical and biophysical research communications, 1987, Apr-29, Volume: 144, Issue:2 Topics: Benzamides; Cell Line; Cell Survival; DNA Damage; Doxorubicin; Humans; Interphase; Kinetics; Leukemi	1987
Formation of the N'-methylnicotinamide adenine dinucleotide derivative of NAD in intact rat pituitary tumor GH3 and human promyelocytic leukemia HL-60 cells. Archives of biochemistry and biophysics, 1986, Aug-15, Volume: 249, Issue:1 Topics: Adenosine Triphosphate; Animals; Cell Line; Guanosine Triphosphate; Humans; Leukemia, Myeloid, Acute	1986

niacinamide and Acute Myelogenous Leukemia